Showing 18,021 - 18,040 results of 60,677 for search '(( 50 ((((mg decrease) OR (mean decrease))) OR (a decrease)) ) OR ( 5 we decrease ))', query time: 1.18s Refine Results
  1. 18021

    A high seroprevalence of antibodies to pertussis toxin among Japanese adults: Qualitative and quantitative analyses by Takumi Moriuchi (4237807)

    Published 2017
    “…Positive correlations were observed between the titers of PT-neutralizing antibodies and anti-PT IgG in all age groups (r<sub>s</sub> values of 0.326–0.522), although the correlation tended to decrease with age. The ratio of PT-neutralizing antibodies to anti-PT IgG was significantly different when we compared the serum and purified IgG fractions among adults (<i>p</i> = 0.016), although this result was not observed among young and older children. …”
  2. 18022
  3. 18023

    Molecular Basis of Calcium-Sensitizing and Desensitizing Mutations of the Human Cardiac Troponin C Regulatory Domain: A Multi-Scale Simulation Study by Peter Michael Kekenes-Huskey (115056)

    Published 2012
    “…Mutations of the cardiac TnC N-terminal regulatory domain have been shown to alter both calcium binding and myofilament force generation. We have performed molecular dynamics simulations of engineered TnC variants that increase or decrease sensitivity, in order to understand the structural basis of their impact on TnC function. …”
  4. 18024

    Longitudinal phenotypic study of late-onset retinal degeneration due to a founder variant c.562C>A p.(Pro188Thr) in the <i>C1QTNF5</i> gene by Julie De Zaeytijd (3633118)

    Published 2021
    “…</p> <p><b>Results</b>: Best-corrected visual acuity (BCVA) and visual fields were maintained up to 50 to 55 years (n = 8), with a gradual decline, but conservation of functional central vision between 55 to 65 years (n = 15), followed by a steep decrease in overall visual function beyond 65 years (n = 9). …”
  5. 18025

    Data Sheet 1_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

    Published 2025
    “…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”
  6. 18026

    Data Sheet 2_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

    Published 2025
    “…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”
  7. 18027

    Data Sheet 3_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

    Published 2025
    “…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”
  8. 18028

    Data Sheet 4_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

    Published 2025
    “…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”
  9. 18029
  10. 18030

    DataSheet_1_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-... by Rafaella F. Q. Grenfell (12841457)

    Published 2022
    “…Background<p>Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.…”
  11. 18031

    Table_3_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

    Published 2022
    “…Background<p>Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.…”
  12. 18032

    Table_2_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

    Published 2022
    “…Background<p>Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.…”
  13. 18033

    Table_4_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

    Published 2022
    “…Background<p>Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.…”
  14. 18034

    Table_1_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

    Published 2022
    “…Background<p>Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.…”
  15. 18035
  16. 18036
  17. 18037

    Normalized (relative to maximum = 100%) knee extensor forces as a function of time. by Ziad Abusara (848106)

    Published 2016
    “…(b) 50% of muscular loading (n = 7), the cartilage-on-cartilage space reached zero and cartilage thickness decreased for these loading conditions. …”
  18. 18038
  19. 18039
  20. 18040

    Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer by Kelly Coffey (129302)

    Published 2012
    “…Although an authentic sample of 4-methyl-5-bromoisothiazole was inactive against Tip60, in an <em>in vitro</em> HAT assay, 1,2-bis(isothiazol-5-yl)disulfane (NU9056) was identified as a relatively potent inhibitor (IC<sub>50</sub> 2 µM). …”